RLM-MD Study
A study to evaluate the safety and efficacy of Relamorelin compared to placebo

Type of Study:
Adults 18 years and older with Type 1 or 2 Diabetes and Gastroparesis

Study Length:
52 weeks

Target Age/Sex:
18 years and older, Male and Female

Benefits:
Participants will receive at no cost: study product, study materials and study-specific procedures

Link: ClinicalTrials.gov

Staus: Closed

Description:

A 52-week study that compares the efficacy of Relamorelin with that of placebo in participants with diabetic gastroparesis with respect to the core signs and symptoms of diabetic gastroparesis.

This Study is Closed.